New drug combo aims to shrink tough liver tumors
NCT ID NCT05257590
Summary
This study is testing whether adding a new oral drug called CVM-1118 to an existing immunotherapy (nivolumab) can better control advanced liver cancer that cannot be surgically removed. It is for about 95 adults whose cancer has progressed after standard treatments. The main goal is to see how many patients' tumors shrink or stop growing with this combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Chang Gung Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
Contact
-
Keelung Chang Gung Memorial Hospital
RECRUITINGKeelung, Taiwan
Contact
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, 100, Taiwan
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
Contact
Conditions
Explore the condition pages connected to this study.